CanalisE.Clinical Review 83: Mechanism of glucocorticoid action in bone: implications to glucocorticoid -induced osteoporosis. J Clin Endocrinol Metab1996; 81: 3441–7.
2.
AlmondM.K., KwanJ.T., EvansK., CunninghamJ.Loss of regional bone mineral density in the first 12 months following renal transplantation. Nephron1994; 66: 52–7.
3.
Ramsey-GoldmanR., DunnJ.E., DunlopD.D.Increased risk of fracture in patients receiving solid organ transplants. J Bone Miner Res1999; 14: 456–63.
4.
HeafJ.G.Bone disease after renal transplantation. Transplantation2003; 75: 315–20.
5.
ParfittA.M.Hypercalcemic hyperparathyroidism following renal transplantation: differential diagnosis, management and implications for cell population control in the parathyroid gland. Miner Electrolyte Metab1999; 8: 92–112.
6.
RixM., LewinE., OlgaardK.Post transplant bone disease. Transplantation Reviews2003; 17: 176–86.
7.
LewinE.Involution of the parathyroid glands after renal transplantation. Curr Opin Nephrol Hypertens2003; 12: 363–71.
8.
TraindlO., LangleF., ReadingS.Secondary hyperparathyroidism and acute tubular necrosis following renal transplantation. Nephrol Dial Transplant1993, 8: 173–6.
MontalbanM., De FranciscoA.L., MarinosoMl, ZubimendiJA, AriasM.Bone disease in long term adult kidney transplant patients with normal renal function. Kidney Int2003; 85(suppl): S1129–32.
11.
LindbergJ.S., MoeS.M., GoodmanW.G.The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int2003; 63: 248–54.
12.
SrinivasT., ScholdJ., KeaW.Improvement in hypercalcemia with cinacalcet after kidney tranplantation. Clin J Amer Soc Nephrol2006; 1: 323–6.
13.
SerraA.L., SavocaR., HuberA.R.Effective control of persistent hyperparathyroidism with cinacalcet in renal allografts recipients. Nephrol Dial transplant2007; 22: 577–83.
14.
SchwarcI., ArgilesA, GarrigueV.Cinacalcet chloride is efficient and safe in renal transplant recipients with post-transplant hyperparathyroidism. Transplantation2006; 82: 675–82.
15.
KruseA.E., EisenbergerU., FelixJ.F., MohauptM.G.Effect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant2007; 22: 2362–5.
GreenJ., DebbyH., LedererE., LeviM., ZajicekH.K., BickT.Evidence for a PTH independent humoral mechanism in post transplant hypophosphatemia and phosphaturia. Kidney Int2003; 64: 2272–9.
20.
PandeS., RitterC.S., RothsteinM.FGF - 23 and sFRP-4 in chronic kidney disease and post renal transplantation. Nephron Physiol2006; 104: 23–8.
BalalM., PaydasS., SeyrekN.Dipyridamole for renal phosphate leak in successfully renal transplant hypophosphatemic patients. Clin Nephrol2005; 63: 87–90.
23.
BrandenburgM.V., WestenfeldR., KettelerM.The fate of bone after renal transplantation. J Nephrol2004; 17: 190–204.
24.
RubinR., BilezekianJ.P.Clinical review151: The role of parathyroid hormone in the patogenesis of glucocorticoidinduced osteoporosis: a re-examination of the evidence. J Clin Endocrinol Metab2002; 87: 4033–441.
25.
JulianB.A., LasowD.A., DubovskyJ., CurtisJ.J., QuarlesL.D.Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med1991; 325: 544–50.
26.
PatelS., KwanJ.T., McCloskeyE.Prevalence and causes of low bone density and fractures in kidney tranplants patients. J Bone Miner Res2001; 16: 1863–70.
27.
MoeS.M.The treatment of steroid bone loss in transplantation. Curr Opin Nephrol Hypertens1997; 6: 544–9.
28.
EpsteinS.Post-transplantation bone disease: the role of immunosuppressive agents and the skeleton. J Bone Miner Res1996; 11: 1–7.
HofbauerL.C., GoriF., RiggsB.L., LaceyD.L., DunstanC.R., SpelsbergT.C., KhoslaS.Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanism of glucocorticoid -induced osteoporosis. Endocrinology1999; 140: 4382–9.
31.
StewartP.J., SternP.H.Cyclosporines: correlation of immunosoppressive activity and inhibition of bone resorption. Calcif Tissue Int1989; 45: 222–6.
32.
WesteelF.P., MazouzH., EzaitouniF.Cyclosporine bone remodeling effect prevents steroid osteopenia after kidney transplantation. Kidney Int2000; 58: 1788–96.
33.
GoffinE., DevogelaerJ.P., LalaouiA.Tacrolimus and low-dose steroid immunosuppression preserves bone mass after renal transplantation. Transpl Int2002; 15: 73–80.
34.
MonegalA., NavasaM., GuanabensM.Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine. Calcified Tissue Int2001; 68: 83–6.
35.
BryerH.P., IsserowJ.A., AmstrongE.C.Azathioprine alone is bone sparing and does not alter cyclosporin A-induced osteopenia in rat. J Bone Miner Res1995; 10: 132–8.
36.
GoodmanG.R., DissanayakeI.R., SodamB.R.Im-munosuppressant use without bone loss-implications for bone loss after transplantation. J bone Miner Res2001; 16: 72–8.
Cueto-ManzanoA.M., KonelS., HutchinsonA.J.Bone loss in long term transplantation: histopathology and densitometry analysis. Kidney Int1999; 55: 2021–9.
39.
AlemA.M., SherrardD.J., GillenD.L.Increased risk of hip fracture among patients with end stage renal disease. Kidney Int2000; 58: 396–9.
40.
NisbethU., LindhE., LjunghallS., BackmanU., FellstromB.Increased fracture rate in diabetes mellitus and female after renal transplantation. Transplantation1999; 67: 1218–22.
41.
AbbottK.C., OglesbyR.J., BohenM.Hospitalized avascular necrosis after renal transplantation in the United States. Kidney Int2002; 62: 2259–2256.
42.
LaustenG.S., LemserT., JensenPK, EgfijordM.Necrosis of the femoral head after kidney transplantation. Clin Transplant1998; 12: 572–4.
43.
JosephsonM.A., SchummL.P., ChiuM.Y., MarshallC., ThristlethwaiteJ.R., SpragueS.M.Calcium and calcitriol prophylaxis attenuates posttranplant bone loss. Transplantation2004; 78: 1233–6.
44.
RingeJ.D., CosterA., MengT., SchachtE., UmbachR.Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium versus vitaminD/calcium. Calcif Tissue Int1999; 65: 337–40.
45.
ReginsterJ.Y., LecartM.P., SarletN., DefraigneJ.O.Alphacalcidol in prevention of glucocorticoid-induced osteoporosis. Calcif Tssue Int1999; 65: 328–31.
46.
De SevauxR.G., HoitsmaA.J., CorstensF.H., WetzelsJ.F.Treatment of vitamin D and calcium reduces bone loss after renal transplantation: a randomized study. J Am Soc Nephrol2002; 13: 1608–12.
47.
WissingK.M., BroedersN., Moreno ReyesR.A controlled study of vitamin D£ to prevent bone loss in renal transplant patients receiving low doses of steroids. Transplantation2005; 79: 108–12.
48.
RouxC., OrienteP., LaanR.Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid - induced bone loss. J Clin Endocrinol Metab1998; 83: 1128–33.
49.
HaasM., Leko-MohrZ., RoschgerP.Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int2003; 63: 1130–6.
50.
ArlenD.J., LambertK., IoannidisG., AdachiJ.D.Treatment of established bone loss after renal transplantation with etidronate. Transplantation2001; 71: 669–73.
51.
CunninghamJ., SpragueS.M.Cannata Andia. Osteoporosis in chronic kidney disease: Am J kidney Dis2004; 43: 566–71.
52.
MitterbauerC., SchwarzC., HaasM., OberbauerR.Effects of bisphosphonates on bone loss in the first year after renal transplantation - a meta-analysis of randomized controlled trial. Nephrol Dial Transplant2006; 21: 2275–81.
53.
WeberT.J., QuarlesL.D.Preventing bone loss after renal transplantation with bisphosphonates: We can…but should we ? Kidney Int2000; 57: 735–8.
54.
CunninghamJ.Bisphosphonates in the renal patient. Neprhol Dial Transplant2007; 22: 1505–7.
55.
CocoM., GlicklichD., FaugereM.C.Prevention of bone loss in renal transplant recipients: a prospective randomized trial of intravenous pamidronate. J Am Soc Nephrol2003; 14: 2669–76.
56.
PalmerS.C., StrippoliG.F., Mc GregorD.O.Interventions of preventing bone disease in kidney tranplant recipients. Cochrane Database Syst R2: CD005015, 2005.
57.
ChenP., MillerP.D., DelmasP.D.Change in Lumbar spine BMD and Vertebral Fracture Risk Reduction in Teriparatide-Treated Postmenopausal Woman With osteoporosis. J Bone Miner Res2006; 17: 273–7.
58.
NevittM.C., ChenP., DoreR.K.Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int2006; 17: 273–9.
59.
BlackD.M., BilezikianJ.P., EnsrudK.E.One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med2005; 353: 555–62.
